| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
24015 |
| Drug |
Capivasertib |
| Brand |
Truqap® |
| Indication |
Capivasertib (Truqap®) is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. |
| Rapid review commissioned |
30/04/2024 |
| Rapid review completed |
29/05/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of capivasertib in combination with fulvestrant compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/07/2024 |
| Pre-submission consultation with Applicant |
03/09/2024 |
